Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPL-I vs M22 IPL for Meibomian Gland Dysfunction
NCT06034626Phase 3Completed
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Nov 2020
- Primary completion
- Aug 2021
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in meibomian gland dysfunction (MGD), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Standard Patient Evaluation of Eye Dryness at 4 months and Corneal Fluorescein Staining at 4 months. Started Nov 2020; status: completed.
02
Conditions
meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on NCT06034626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06034626.